ClinicalTrials.gg
CompletedNCT01664624Updated Feb 1, 2017Results posted

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

A Phase 1 interventional study of Roflumilast and Alogliptin in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-01.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing alogliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus, Type 2.

Enrollment
36th of 39
40 · median 329
Started
2012
the only one that year
Phase 1
2 of 39
none open now
Registered
28th of 39
by date
Lead sponsor
1 of 39
AstraZeneca

Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, this one is the 36th largest by enrollment, is the only one that started in 2012, is one of 2 in phase 1, and was the 28th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About alogliptin

alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.

Read the detailed description

This is a study to evaluate the antiglycemic efficacy and safety of roflumilast + alogliptin compared to alogliptin alone and roflumilast alone; it will also include an open-label exenatide treatment arm as a control. The antiglycemic efficacy of the combination will be evaluated through the measurement of postprandial active GLP-1 level, ß cell secretion activity (via the measurement of C-peptide and insulin levels), appetite sensations (as assessed by VAS) and glycemic control as assessed by a continuous glucose monitoring system (CGMS).

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18 to 80 years, inclusive, at the time of dosing on Day 1.
  2. Has an historical diagnosis of type 2 diabetes mellitus (T2DM) disease.
  3. Has a documented history of a diet and exercise plan and is receiving metformin as monotherapy at a stable dose for at least 8 weeks prior to Screening; has no chronic use (>7 days) of any other antidiabetic therapy within the 8 weeks prior to Screening.
  4. Has inadequate glycemic control at Screening, as evidenced by (glycosylated ) level between 7.0% and 10.0%, inclusive.
  5. Has a (BMI) of ≥23.0 kg/m\^2 and ≤45.0 kg/m\^2, at Screening.
  6. A female of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of throughout the duration of the study and for 30 days after the last dose of study drug.
  7. A male who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose of study drug
  8. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  9. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Has a history of type 1 diabetes.
  2. Has a history of acute metabolic diabetic complications.
  3. Has has abnormal Screening or Check-in (Day -2) laboratory values that suggest a underlying disease (eg, active liver disease or jaundice) or participant with the following laboratory abnormalities: (ALT) and/or aspartate aminotransferase (AST) >3 × (ULN).
  4. Has a history of diabetic gastroparesis or history of gastric bypass surgery.
  5. Has a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months prior to Screening.
  6. Has heart failure of Class (III-IV) regardless of therapy.
  7. Has a supine blood pressure >150 mm Hg for systolic or >90 mm Hg for diastolic, confirmed on repeat testing within a maximum of 5 minutes, at Screening and Check-in (Day -2).
  8. Has presence or history of neuropsychiatric disorder (eg, psychosis, psychotic disorders, depression associated with suicidal thinking, suicidal ideation or behavior).
  9. Has a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within the past 2 years or is unwilling to agree to abstain from alcohol and drugs throughout the study.
  10. Has a ≤120 g/L for men and ≤100 g/L for women.
  11. Has a history of clinically significant allergies or idiosyncrasies to roflumilast, alogliptin and exenatide or any inactive ingredient(s) of these products, eg, rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption or phenylketonuria.
  12. Has received alogliptin or roflumilast in a previous clinical study or as a therapeutic agent within 2 months prior to Screening, or is taking prescription roflumilast for (COPD), or has received any other compound within 30 days prior to the first dose of study medication, or is participating or plans to participate in any other clinical trial during this study.
  13. If female, is pregnant or lactating or intending to become pregnant before, during, or within 30 days after last dose; or intending to donate ova during such time period.
  14. If male, intends to donate sperm during the course of the study or for 30 days after last dose of study medication.
  15. Is an immediate family member, study site employee, or in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  16. Has a history of cancer, except basal cell or squamous cell carcinoma which has been in remission for at least 5 years prior to Day 1.
  17. Serum creatinine ≥1.5 mg/dL for males and ≥1.4 mg/dL for females or \<60 mL/minutes, based on calculation by central lab using the Cockcroft-Gault approximation at Screening Visit.
  18. Has a history of any hemoglobinopathy that may affect determination of .
  19. Has positive test result for surface antigen (HBsAg), antibody (HCV), any known history of infection with (HIV), any acute infection, or severe immunological diseases (eg, multiple sclerosis, systemic lupus erythematosus, and progressive multifocal leukoencephalopathy).
  20. Has a risk of suicide according to the Investigator's clinical judgment per Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening or has made a suicide attempt in the past 6 months.
  21. Has any clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation (as assessed by the investigator).
  22. Does not have an adequate standard of literacy to allow him or her to complete the study diary during non-clinic days.
  23. Has poor peripheral venous access.
  24. Has Screening or Check-in (Day -2) abnormal clinically significant (ECG). Entry of any participant with abnormal not clinically significant ECG must be approved and documented by signature of Principal Investigator and Medical Monitor.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Roflumilast + alogliptin

    Roflumilast 500 μg, tablets, orally and alogliptin 25 mg, tablets, orally, once a day for 11 days.

    Drug: Roflumilast · Drug: Alogliptin

  • Experimental
    Alogliptin alone

    Placebo to roflumilast, tablets, orally and alogliptin, 25 mg, tablets, orally, once a day for 11 days.

    Drug: Alogliptin · Drug: Placebo to roflumilast

  • Experimental
    Roflumilast alone

    Roflumilast 500 μg, tablets, orally and placebo to alogliptin, tablets, orally, once a day, for 11 days.

    Drug: Roflumilast · Drug: Placebo to alogliptin

  • Active comparator
    Exenatide

    Exenatide 5 μg subcutaneous injection twice a day for 11 days.

    Drug: Exenatide

Interventions

  • Roflumilast tablets

    Also known as: Daxas, Daliresp

  • Alogliptin tablets

    Also known as: Nesina

  • Exenatide solution

    Also known as: Byetta, Bydureon

  • DrugPlacebo to roflumilast

    Placebo-matching roflumilast tablets

  • DrugPlacebo to alogliptin

    Placebo-matching alogliptin tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1

    The concentration of glucagon-like peptide-1 (GLP-1) in blood before and up to 8 hours after eating (postprandial) was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an analysis of covariance (ANCOVA) model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of active GLP-1 as a continuous covariate.

    Time frame: Baseline and Day 11; samples were taken at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal).

Secondary outcomes

  1. Change From Baseline in AUC(0-8) of Postprandial Plasma Glucose

    The concentration of glucose in blood before and up to 8 hours after eating (postprandial) was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and baseline postprandial AUC (0-8) of plasma glucose as a continuous covariate.

    Time frame: Baseline and Day 11 at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal).

  2. Change From Baseline in Postprandial AUC(0-8) of C-peptide

    The concentration of C-peptide in blood before and up to 8 hours after eating (postprandial) was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of C-peptide as a continuous covariate.

    Time frame: Baseline and Day 11; samples were taken at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal).

  3. Change From Baseline in Postprandial AUC(0-8) of Insulin

    The concentration of insulin in blood before and up to 8 hours after eating was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of insulin as a continuous covariate.

    Time frame: Baseline and Day 11; samples were taken at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal).

  4. Change From Baseline to Day 11 in AUC(0-8) of Appetite Sensation

    Appetite sensations were measured using a visual analog scale (VAS) questionnaire. Participants were asked to indicate their level of fullness, hunger, satiety, and prospective consumption (how much do you think you can eat?) on a 100 mm line ranging from "Not at all" (0 mm) to "extremely" (100 mm). Appetite sensation scores before and up to 8 hours after eating were plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of appetite sensation VAS score as a continuous covariate.

    Time frame: At Baseline and Day 11, every 30 minutes, starting 1 hour before eating until 8 hour after the meal.

  5. Change From Baseline to Day 11 in 24-hour Average Plasma Glucose

    Plasma glucose was measured by Continuous Glucose Monitoring System (CGMS). CGMS measures glucose every 5 minutes, starting in the fasting state 8 hour prior to the standardized breakfast (12 AM) until 16 hours after the breakfast. The average 24-hour plasma glucose concentration was calculated. Least squares means were obtained using an ANCOVA model with treatment as fixed effect, and Baseline 24-hour Glucose Measured by CGMS as a continuous covariate.

    Time frame: Baseline (Day -1) and Day 11, from 12 AM through 24 hours.

07

Results

Posted Feb 20, 2014

Participant flow

Participants took part in the study at 2 investigative sites in the United States from 10 July 2012 to 29 November 2012.

Participant flow — Overall Study
MilestoneRoflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatide
Started1011109
Completed1010109
Not completed0100
Withdrew: Adverse event0100

Outcome measures

PrimaryChange From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1

The concentration of glucagon-like peptide-1 (GLP-1) in blood before and up to 8 hours after eating (postprandial) was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an analysis of covariance (ANCOVA) model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of active GLP-1 as a continuous covariate.

Time frame:
Baseline and Day 11; samples were taken at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal).
Reported as:
Least squares mean · pmol/L*hr
Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1
pmol/L*hrRoflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatide
Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-126.5 ± 4.0431.6 ± 4.013.8 ± 3.94-2.3 ± 4.14
Statistical analysis
  • Roflumilast + Alogliptin vs Alogliptin Alone · ANCOVA · p = 0.388 (The comparison was evaluated at the 5% level of significance.) · Ls mean difference: -5.1 · 95% CI -16.9 to 6.7ANCOVA model with treatment as fixed effect, and baseline Postprandial AUC (0-8) of active GLP-1 as a continuous covariate.
  • Roflumilast + Alogliptin vs Roflumilast Alone · ANCOVA · p = <0.001 (The comparison was evaluated at the 5% level of significance.) · Ls mean difference: 22.7 · 95% CI 11.1 to 34.3ANCOVA model with treatment as fixed effect, and Baseline Postprandial AUC (0-8) of active GLP-1 as a continuous covariate.
  • Roflumilast + Alogliptin vs Exenatide · ANCOVA · p = <0.001 (The comparison was evaluated at the 5% level of significance.) · Ls mean difference: 28.8 · 95% CI 17.1 to 40.5ANCOVA model with treatment as fixed effect, and Baseline Postprandial AUC (0-8) of active GLP-1 as a continuous covariate.
SecondaryChange From Baseline in AUC(0-8) of Postprandial Plasma Glucose

The concentration of glucose in blood before and up to 8 hours after eating (postprandial) was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and baseline postprandial AUC (0-8) of plasma glucose as a continuous covariate.

Time frame:
Baseline and Day 11 at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal).
Reported as:
Least squares mean · mmol/L*hr
Change From Baseline in AUC(0-8) of Postprandial Plasma Glucose
mmol/L*hrRoflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatide
Change From Baseline in AUC(0-8) of Postprandial Plasma Glucose-13.4 ± 2.70-9.8 ± 2.71-9.0 ± 2.71-18.5 ± 2.85
SecondaryChange From Baseline in Postprandial AUC(0-8) of C-peptide

The concentration of C-peptide in blood before and up to 8 hours after eating (postprandial) was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of C-peptide as a continuous covariate.

Time frame:
Baseline and Day 11; samples were taken at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal).
Reported as:
Least squares mean · ng/mL*hr
Change From Baseline in Postprandial AUC(0-8) of C-peptide
ng/mL*hrRoflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatide
Change From Baseline in Postprandial AUC(0-8) of C-peptide1.0 ± 1.151.4 ± 1.16-0.7 ± 1.170.0 ± 1.22
SecondaryChange From Baseline in Postprandial AUC(0-8) of Insulin

The concentration of insulin in blood before and up to 8 hours after eating was plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of insulin as a continuous covariate.

Time frame:
Baseline and Day 11; samples were taken at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal).
Reported as:
Least squares mean · pmol/L*hr
Change From Baseline in Postprandial AUC(0-8) of Insulin
pmol/L*hrRoflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatide
Change From Baseline in Postprandial AUC(0-8) of Insulin-49.5 ± 181.09107.8 ± 180.7526.9 ± 180.38-136.4 ± 190.12
SecondaryChange From Baseline to Day 11 in AUC(0-8) of Appetite Sensation

Appetite sensations were measured using a visual analog scale (VAS) questionnaire. Participants were asked to indicate their level of fullness, hunger, satiety, and prospective consumption (how much do you think you can eat?) on a 100 mm line ranging from "Not at all" (0 mm) to "extremely" (100 mm). Appetite sensation scores before and up to 8 hours after eating were plotted and the area under the curve calculated using the linear trapezoidal rule at Baseline and on Day 11. Least squares means of the change from Baseline to Day 11 were obtained using an ANCOVA model with treatment as fixed effect, and Baseline postprandial AUC (0-8) of appetite sensation VAS score as a continuous covariate.

Time frame:
At Baseline and Day 11, every 30 minutes, starting 1 hour before eating until 8 hour after the meal.
Reported as:
Least squares mean · mm*hr
Change From Baseline to Day 11 in AUC(0-8) of Appetite Sensation
mm*hrRoflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatide
Fullness70.5 ± 59.7362.0 ± 56.52136.0 ± 57.81116.8 ± 59.51
Hunger-103.6 ± 52.613.1 ± 52.18-132.7 ± 52.44-122.5 ± 54.92
Prospective consumption-97.1 ± 54.24-14.9 ± 53.76-169.5 ± 53.98-124.3 ± 56.53
Satiety-82.7 ± 53.66-3.2 ± 52.96-139.2 ± 53.58-127.7 ± 55.80
SecondaryChange From Baseline to Day 11 in 24-hour Average Plasma Glucose

Plasma glucose was measured by Continuous Glucose Monitoring System (CGMS). CGMS measures glucose every 5 minutes, starting in the fasting state 8 hour prior to the standardized breakfast (12 AM) until 16 hours after the breakfast. The average 24-hour plasma glucose concentration was calculated. Least squares means were obtained using an ANCOVA model with treatment as fixed effect, and Baseline 24-hour Glucose Measured by CGMS as a continuous covariate.

Time frame:
Baseline (Day -1) and Day 11, from 12 AM through 24 hours.
Reported as:
Least squares mean · mg/dL
Change From Baseline to Day 11 in 24-hour Average Plasma Glucose
mg/dLRoflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatide
Change From Baseline to Day 11 in 24-hour Average Plasma Glucose-25.4 ± 6.67-17.5 ± 6.67-14.5 ± 6.66-34.9 ± 7.02

Adverse events

Collected over From the first dose of study medication to no more than 30 days after the last dose of the study medication (a maximum of 41 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast + Alogliptin—1/10 (10%)6/10 (60%)
Alogliptin Alone—0/11 (0%)5/11 (45.5%)
Roflumilast Alone—0/10 (0%)8/10 (80%)
Exenatide—0/9 (0%)7/9 (77.8%)
Most frequent serious events
Most frequent serious events
EventRoflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatide
InfluenzaInfections and infestations1/100/110/100/9
Most frequent other events
Showing 10 of 21
Most frequent other events
EventRoflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatide
NauseaGastrointestinal disorders2/101/115/102/9
DiarrhoeaGastrointestinal disorders0/103/114/104/9
HeadacheNervous system disorders3/102/112/102/9
VomitingGastrointestinal disorders1/101/113/100/9
EcchymosisSkin and subcutaneous tissue disorders0/100/110/102/9
Decreased appetiteMetabolism and nutrition disorders1/102/112/101/9
DizzinessNervous system disorders0/100/112/100/9
AnaemiaBlood and lymphatic system disorders0/100/111/101/9
ContusionInjury, poisoning and procedural complications0/100/110/101/9
InsomniaPsychiatric disorders1/100/111/100/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Roflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatideTotal
Mean50.7 ± 10.1552.9 ± 7.5260.7 ± 4.2454.6 ± 6.8854.7 ± 8.15
Age, Customized
Age, Customized(participants)Roflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatideTotal
< 65 years10119939
≥ 65 years00101
Gender
Gender(Participants)Roflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatideTotal
Female434415
Male686525
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Roflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatideTotal
Hispanic or Latino767626
Non-Hispanic or Latino353314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Roflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatideTotal
Black or African American33208
White788932
Region of Enrollment
Region of Enrollment(participants)Roflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatideTotal
United States101110940
Height
Height(cm)Roflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatideTotal
Mean171.1 ± 8.91171.2 ± 6.03166.6 ± 10.44166.4 ± 5.90169.0 ± 8.09
Weight
Weight(kg)Roflumilast + AlogliptinAlogliptin AloneRoflumilast AloneExenatideTotal
Mean103.12 ± 21.68893.24 ± 11.67089.33 ± 17.96186.98 ± 14.71393.32 ± 17.329

4 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Chula Vista, California, United States
  • Orlando, Florida, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2012
First posted
Aug 14, 2012
Start
Jul 2012
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Feb 20, 2014
Last update
Feb 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01664624
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 14, 2012
Start date
Jul 2012
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Feb 20, 2014
Last update
Feb 1, 2017

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Roflumilast · Alogliptin

Start the discussion